Amedisys reported a net service revenue increase to $598.1 million in Q4 2024, up from $570.8 million in Q4 2023. However, the company experienced a net loss attributable to Amedisys, Inc. of $20.4 million, or $0.62 per diluted share, primarily due to merger-related expenses and a non-cash goodwill and other intangibles impairment charge.
Net service revenue increased by $27.3 million to $598.1 million in Q4 2024.
The company reported a net loss attributable to Amedisys, Inc. of $20.4 million in Q4 2024, compared to a net income of $19.3 million in Q4 2023.
Diluted EPS was -$0.62 in Q4 2024, a decrease from $0.59 in Q4 2023.
Adjusted EBITDA for Q4 2024 was $54.6 million, a slight decrease from $56.7 million in Q4 2023.
Amedisys will not conduct a quarterly earnings call to discuss the fourth quarter and year-end results due to the pending merger with UnitedHealth Group Incorporated.